A detailed history of Bank Of America Corp transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 262,230 shares of AKRO stock, worth $8.48 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
262,230
Previous 425,871 38.43%
Holding current value
$8.48 Million
Previous $10.8 Million 42.82%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$18.31 - $24.62 $3 Million - $4.03 Million
-163,641 Reduced 38.43%
262,230 $6.15 Million
Q1 2024

May 15, 2024

SELL
$17.76 - $31.18 $1.13 Million - $1.99 Million
-63,770 Reduced 13.02%
425,871 $10.8 Million
Q4 2023

Feb 14, 2024

BUY
$11.38 - $50.33 $3.88 Million - $17.1 Million
340,722 Added 228.8%
489,641 $11.4 Million
Q2 2023

Aug 14, 2023

SELL
$36.89 - $56.88 $3.04 Million - $4.69 Million
-82,502 Reduced 35.65%
148,919 $6.95 Million
Q1 2023

May 12, 2023

BUY
$37.27 - $50.24 $1.08 Million - $1.46 Million
29,032 Added 14.34%
231,421 $8.85 Million
Q4 2022

Feb 10, 2023

BUY
$33.44 - $54.8 $4.42 Million - $7.24 Million
132,069 Added 187.81%
202,389 $11.1 Million
Q3 2022

Nov 14, 2022

BUY
$10.15 - $34.05 $323,196 - $1.08 Million
31,842 Added 82.75%
70,320 $2.39 Million
Q2 2022

Aug 12, 2022

SELL
$8.0 - $15.01 $190,104 - $356,682
-23,763 Reduced 38.18%
38,478 $363,000
Q1 2022

May 16, 2022

BUY
$12.97 - $22.26 $291,202 - $499,781
22,452 Added 56.43%
62,241 $883,000
Q4 2021

Feb 08, 2022

SELL
$19.87 - $26.24 $283,346 - $374,182
-14,260 Reduced 26.38%
39,789 $842,000
Q3 2021

Nov 15, 2021

BUY
$18.65 - $25.46 $844,826 - $1.15 Million
45,299 Added 517.7%
54,049 $1.21 Million
Q2 2021

Sep 13, 2021

BUY
$24.81 - $32.35 $217,087 - $283,062
8,750 New
8,750 $217,000

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.5B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.